glp-1 antagonist Frontiers Exploring the Side Effects of
Description
2011;34:S276S278
Major adverse cardiovascular events (MACE) The research examined eight large cohorts of T2DM patients, with cardiovascular outcome trials (CVOTs), for main MACE outcomes, including cardiovascular death, nonfatal MI, and nonfatal stroke, which were studied with GLP1RAs [40]
Katafuchi, T., Yasue, H., Osaki, T
[Accessed on 23.11.2014]
